Health news round-up: Alzheimer’s treatment, retatrutide results and kidney cancer guidelines A weekly summary of important developments in pharmacy and health news that you may have missed.…
Apixaban safer than rivaroxaban for thrombosis treatment, study finds Researchers found that patients who took anticoagulant apixaban for the treatment of venous thrombosis experienced less “clinically relevant bleeding”, compared with those who received rivaroxaban.…
It is ‘vital’ that patients access weight-loss jabs from pharmacies, says London health committee A report by the London Assembly Health Committee recommended strict safeguards to ensure that only the eligible can purchase weight-loss drugs, as well as comprehensive wrap-around care for patients.…
London’s first drug-checking service could expand to more cities Under the drug-checking service, users can submit substances for testing and will subsequently receive “anonymous, non-judgemental chat”, alongside tailored harm reduction advice.…
Government pledges support for more safer drug consumption facilities in ten-year alcohol and drug strategy The Scottish government's alcohol and drugs strategic plan for 2026–2035 also sets out plans to further expand the distribution of naloxone, including through community pharmacies.…
JAK inhibitors: risks and safety principles An overview of the mechanism of action of Janus kinase inhibitors, as well as the risks and common side effects of their use in treating chronic inflammatory disorders.…
Prescribing dilemma: balancing risk and benefit when prescribing anticoagulation in an older patient with falls risk This real-world dilemma examines the decision-making process when considering anticoagulation in older patients.…
Health news round-up: puberty blockers, oral GLP-1s and inequalities in neonatal care A weekly summary of important developments in pharmacy and health news that you may have missed.…
Orforglipron offers greater weight loss for people with diabetes than oral semaglutide Researchers found that although patients who took orforglipron lost more body weight on average compared with semaglutide, more patients stopped taking the drug owing to adverse effects.…
Pharmacies respond to GP funding incentives for weight-loss drugs The government said that two indicators that track the provision of obesity care to eligible patients will be added to the Quality and Outcomes Framework under the GP contract for 2026/2027.…
